International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 3 May-June 2025, pp: 1951-1958 www.ijprajournal.com ISSN: 2456-4494

Gaucher Disease Unveiled: From Genes to Targeted Therapy

Dr. Alisha Naaz*[1], Dr. Afsha Anjum[1], Dr.Pranju Aswal[1], Anas Khan[2]
1. Pharm D Research Scholar, Department of Pharmacy Practice, School of Pharmaceutical Sciences, Shri Guru Ram Rai University, Dehradun-248001, Uttarakhand, India.
2. M. Pharm Research Scholar, Department of Quality Assurance, School of Pharmaceutical Sciences, Shri Guru Ram Rai University, Dehradun-248001, Uttarakhand, India.

Date of Submission: 15-06-2025 Date of Acceptance: 25-06-2025

ABSTRACT: Gaucher disease (GD), an autosomal recessive lysosomal storage disorder first described by Philippe Gaucher in 1882, results from mutations in the GBA1 gene, leading to deficient glucocerebrosidase activity and subsequent accumulation of glucocerebroside in macrophages. This causes multisystem involvement, primarily affecting the liver, spleen, and bone marrow. With an incidence of 1:40,000-60,000 globally, GD shows ethnic variability, being more prevalent among Ashkenazi Jews (1:850). Type 1 (non-neuronopathic) accounts for 90% of cases, while types 2 and 3 (neuronopathic) and rare perinatal/cardiovascular forms present with severe neurological or systemic complications. Diagnosis relies on leukocyte enzyme assay (<15% activity), GBA1 genetic testing, elevated biomarkers (chitotriosidase, glucosylsphingosine), and imaging (MRI, ultrasound). Treatment includes enzyme replacement therapy (imiglucerase, velaglucerase alfa), substrate reduction therapy (eliglustat, miglustat), and supportive care, with emerging options like gene therapy. Despite treatment, patients face complications such as bone disease, Parkinsonism (5-8% risk), and hematologic abnormalities, necessitating lifelong multidisciplinary monitoring. Early diagnosis and tailored therapy significantly improve outcomes, though neuronopathic forms remain challenging to manage.

KEYWORDS: Gaucher disease, metabolic disorder, lipid buildup, GBA1 genetic testing, gene therapy.

I.INTRODUCTION

Gaucher disease (go-SHAY) is a hereditary condition caused by mutations in the GBA1 gene, disrupting the function of the enzyme glucocerebrosidase and affecting metabolic processes. This enzyme normally breaks down glucocerebroside lipids, but its deficiency leads to harmful lipid buildup in tissues. The condition, discovered by French physician Philippe Gaucher in 1882, exemplifies the complicated interplay between genetics, biochemistry, and medicine. It varies in intensity, with symptoms emerging at any age and ranging from mild to severe, including fatal cases. [1]

Inborn errors of metabolism, like Gaucher disease, are often present in newborns or infants, making them particularly important in pediatric care. Gaucher disease manifests in five distinct forms: type 1 (the most common), type 2 (acute neuronopathic), type 3 (chronic neuronopathic), perinatal lethal (causing severe complications during fetal development or infancy), and cardiovascular (primarily affecting the heart). These disorders typically arise from enzyme deficiencies that disrupt metabolic processes, leading to either energy production failures or toxic accumulations of substances like glucocerebroside.

Gaucher disease is classified as a "toxic accumulation" disorder, where lipids build up in cells, causing localized damage. Such metabolic abnormalities are classified into three types: localised toxicity, systemic toxicity, or a combination of the two. Understanding these key features is essential for accurate diagnosis and treatment. [2]

II. ETIOLOGY

Gaucher disease is caused by mutations in the GBA1 gene, leading to reduced activity of the lysosomal enzyme glucocerebrosidase. The enzyme deficiency leads to a buildup of glucocerebroside fats, particularly accumulating in the spleen, liver, and bone marrow tissues. Glucocerebroside is made up of a glucose molecule connected to ceramide's sphingosine component. The disease belongs to a group of inherited metabolic conditions called lysosomal storage disorders (LSDs), which also include Tay-Sachs disease, Fabry disease, and mucopolysaccharidosis. These disorders are progressive, meaning symptoms worsen over time.

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 3 May-June 2025, pp: 1951-1958 www.ijprajournal.com ISSN: 2456-4494

Lysosomes, the cell's digestive organelles, degrade lipids and macromolecules with hydrolytic enzymes. In Gaucher disease, macrophages—cells rich in lysosomes—accumulate undigested glucocerebroside, causing lysosomes to enlarge and take on a "crumpled tissue paper" appearance under electron microscopy. Without treatment, the liver and spleen can enlarge significantly, with the spleen potentially growing up to 15 times its normal size.

Interestingly, even with identical GBA1 mutations, disease severity can vary widely among patients, while different mutations may produce similar symptoms. This variability suggests that environmental factors and genetic background influence disease progression. (3) The exact mechanisms behind these differences remain unclear, highlighting the complexity of Gaucher disease.

III. EPIDEMIOLOGY

Gaucher disease is the most frequent autosomal recessive disorder among Ashkenazi Jews, with a carrier rate of approximately 6%, significantly higher than the 0.7–0.8% observed in non-Jewish populations. Other prevalent genetic conditions in this group include cystic fibrosis (4% carrier frequency) and Tay-Sachs disease (3.7% carrier frequency).

Type 1 Gaucher disease, the most common form, exhibits a highly variable clinical presentation—some individuals remain asymptomatic throughout life, while others develop symptoms in early childhood. Unlike kinds 2 and 3, type 1 usually does not result in neurological issues. In contrast, types 2 and 3 are rare and affect the central nervous system, with type 2 and the perinatal lethal form often leading to infant mortality. Type 3 progresses more slowly but usually results in death by early to mid-adulthood. [4]

IV. PATHOPHYSIOLOGY

Gaucher disease has a wide range of clinical symptoms, which can be classified as visceral, haematologic, skeletal, or metabolic. The most common visceral involvement is hepatosplenomegaly.

Hematologic complications often involve thrombocytopenia, anemia, and leukopenia. These abnormalities arise due to glucocerebroside accumulation—bone marrow infiltration impairs platelet production, while splenic sequestration accelerates the destruction of red and white blood cells. Consequently, patients are more prone to abnormal bleeding and repeated infections.

Skeletal abnormalities are another hallmark, including bone pain crises, avascular necrosis (osteonecrosis), osteopenia, pathological fractures, and Erlenmeyer flask deformities. These issues stem from bone marrow infiltration by lipid-laden macrophages, which disrupt blood flow, nutrient delivery, and oxygen supply, ultimately causing bone necrosis, reduced density, and growth impairments.

Additionally, metabolic disturbances—particularly nutritional deficiencies, insulin resistance, and dyslipidemia—are frequently observed in both pediatric and adult patients. Given their impact on overall health, routine screening for metabolic disorders is essential to optimize patient management and improve outcomes. [5]

V. DIAGNOSIS

The diagnostic hallmark of Gaucher disease is the presence of lipid-laden macrophages (Gaucher cells), which are typically identified in liver sinusoids and bone marrow biopsies. These distinctive cells display a characteristic "wrinkled paper" appearance under microscopy due to intracellular glucocerebroside accumulation and are periodic acid-Schiff (PAS) positive.

Gaucher cells predominantly collect in the liver's sinusoidal channels, with minimal involvement of the hepatocytes themselves. This sparing of hepatocytes occurs because biliary excretion helps eliminate excess glucocerebroside, and phagocytic macrophages normally process glycolipid turnover. Therefore, end-stage liver disease is an uncommon complication of Gaucher disease.

Although bone marrow infiltration by Gaucher cells is a pathognomonic feature, histologic examination alone should not be the primary diagnostic method. Instead, it serves as a supportive tool alongside enzymatic assays and genetic testing for confirmation.

Laboratory investigations:

Evaluation of blood cell deficiencies requires a comprehensive CBC with platelet analysis. Liver function tests typically show mild enzyme elevations, though significant abnormalities warrant further investigation. Coagulation studies should be routinely monitored. [6]

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 3 May-June 2025, pp: 1951-1958 www.ijprajournal.com ISSN: 2456-4494

Definitive diagnostic tests:

The diagnosis is confirmed by measuring glucocerebrosidase activity in leukocytes, with levels below 15% of normal being diagnostic. Genetic testing is instrumental in Ashkenazi Jewish populations, where six common GBA1 mutations (c.84insG, L444P, N370S, IVS2+1g>a, V394L, and R496H) account for the majority of cases. However, full gene sequencing may be required for other ethnic groups. Note that PCR-based mutation analysis has limitations, as it may miss recombinant alleles associated with severe disease.

Biochemical markers:

Elevated levels of angiotensin-converting enzyme, acid phosphatase, and ferritin are characteristic and may normalize with treatment. Chitotriosidase monitoring is valuable, except in 10% of patients with congenital deficiency. Glucosylsphingosine levels may correlate with treatment response.

Imagingstudies:

Abdominal ultrasound can detect organomegaly, while MRI is superior for early bone involvement assessment. Conventional radiography evaluates skeletal and pulmonary manifestations. Bone density is measured via DEXA scanning, and cardiac ultrasound detects pulmonary hypertension. For neuronopathic variants, standard monitoring should include electroencephalography, evoked potential testing, dysphagia assessments, and comprehensive neuro-ophthalmic examinations.

Histopathologicalevaluation:

While bone marrow aspiration historically revealed diagnostic Gaucher cells, enzyme testing has replaced it as the primary diagnostic method due to superior sensitivity and specificity. Liver biopsy is rarely indicated given available non-invasive alternatives, though it may be considered for unexplained hepatomegaly.

VI. SIGNS AND SYMPTOMS

Gaucher disease manifests with variable clinical features depending on disease subtype. The most frequent presenting signs include:

- Painless enlargement of the liver and spleen (hepatosplenomegaly)
- Hypersplenism leading to pancytopenia
- Debilitating bone pain, particularly in weight-bearing joints (hips and knees)
- Type-specific neurological manifestations:
  - Type 1: Olfactory dysfunction and cognitive impairment
  - Type 2: Convulsions, muscle rigidity, developmental delay, and respiratory abnormalities
  - Type 3: Myoclonic jerks, seizure disorders, progressive dementia, and eye movement disorders
- Additional systemic features including parkinsonian symptoms, reduced bone density, and characteristic cutaneous hyperpigmentation

Diagnostic confirmation requires:

1. Diagnosis requires documentation of impaired GBA1 activity in circulating leukocytes.
2. Identification of pathogenic GBA1 gene mutations

Despite the availability of non-invasive diagnostic methods (blood tests), many patients undergo unnecessary invasive procedures (bone marrow aspiration or liver biopsy) before an accurate diagnosis. Enhanced physician knowledge of Gaucher disease's clinical presentation may prevent such adverse outcomes. Notably, patients with hepatosplenomegaly are often initially misdiagnosed with malignancy, highlighting the importance of considering metabolic disorders in differential diagnoses. [7]

VII. TREATMENT

Current treatment strategies for Gaucher disease primarily involve two modalities: enzyme replacement therapy (ERT) and substrate reduction therapy (SRT). ERT involves intravenous administration of functional GBA1 enzyme (β-glucocerebrosidase), with FDA-approved options including imiglucerase (Cerezyme) and velaglucerase alfa (VPRIV) for types 1 and 3 Gaucher disease. [8] While ERT effectively manages visceral and skeletal manifestations, its efficacy is limited in neurological forms due to the blood-brain barrier. Importantly, ERT does not address the genetic defect and may induce antibody formation against the therapeutic enzyme.

SRT involves oral inhibitors that target and decrease glucosylceramide formation. Two FDA-approved agents exist:

1. Eliglustat (for type 1 only) - a glucosylceramide synthase inhibitor with no CNS penetration.
2. Miglustat - demonstrates blood-brain barrier penetration but is currently approved only for mild-to-moderate type 1 disease in adults. [9]

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 3 May-June 2025, pp: 1951-1958 www.ijprajournal.com ISSN: 2456-4494

Hematopoietic stem cell transplantation remains a potential curative option, particularly for type 3 disease, though its use is limited by significant risks. [10,11,12,13,14,15] Splenectomy is reserved for refractory thrombocytopenia or severe abdominal pain, requiring appropriate prophylactic measures against post-splenectomy infections. [16]

Emerging therapeutic avenues include gene editing and gene therapy approaches that may address the fundamental genetic pathology. Current treatments require careful selection based on:

- Disease type and severity
- Neurological involvement
- Patient age and comorbidities
- Treatment accessibility and tolerance. [17,18]

VIII. DIFFERENTIAL DIAGNOSIS

Gaucher disease shares clinical features with several other conditions, requiring careful differentiation. The main disorders to consider in the differential diagnosis include:

Hematologic malignancies (particularly multiple myeloma)

Neurodegenerative disorders:

- Lewy body dementia
- Parkinson disease

Other lysosomal storage disorders:

- Niemann-Pick disease (types A and B)
- Sphingomyelinase deficiency

These conditions may present with overlapping manifestations such as hepatosplenomegaly, cytopenias, neurological symptoms, or skeletal abnormalities. Accurate diagnosis requires comprehensive evaluation, including enzyme assays, genetic testing, and clinical correlation. [19,20,21,22]

IX. PROGNOSIS

The clinical outlook for Gaucher disease patients varies substantially based on disease subtype, treatment timing, and individual factors:

Type 1 (non-neuropathic):

- Most favorable prognosis among all types
- Near-normal life expectancy is achievable with proper management
- ERT effectively improves hematologic and visceral manifestations
- Skeletal complications may persist despite treatment [23]

Type 2 (acute neuropathic):

- Most aggressive form with the poorest prognosis
- Rapid neurological deterioration in infancy
- Most cases result in mortality by age 2-3 years.
- Limited treatment response due to CNS involvement

Type 3 (chronic neuropathic):

- Intermediate severity between types 1 and 2
- Variable progression rate (some stable, others progressive)
- Reduced life expectancy compared to type 1
- Partial treatment response is possible for systemic symptoms

Perinatal lethal form:

- Extremely severe prenatal/neonatal presentation
- Invariably lethal, typically within the neonatal period (days to weeks post-delivery)
- Primarily palliative care approach [24]

Cardiovascular variant:

- Rare form with predominant cardiac involvement
- Prognosis depends on the degree of valvular/vascular compromise
- Limited response to conventional therapies
- Requires specialized cardiac monitoring

Critical prognostic factors across all types include:

- Early diagnosis and treatment initiation
- Regular multidisciplinary monitoring
- Appropriate therapeutic selection (ERT/SRT)
- Management of disease complications [25]

X. COMPLICATIONS

Gaucher disease's characteristic glucocerebroside accumulation disrupts normal organ function through multiple biological processes.

1. **Skeletal system involvement**

- Progressive bone density loss (osteopenia progressing to osteoporosis)
- Increased fracture risk, particularly vertebral compression fractures
- Avascular necrosis, especially of femoral heads
- Chronic debilitating bone pain syndrome

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 3 May-June 2025, pp: 1951-1958 www.ijprajournal.com ISSN: 2456-4494

2. **Visceral organ effects**
- Marked hepatosplenomegaly causing mechanical complications
- Portal hypertension secondary to hepatic infiltration
- Splenic sequestration leading to cytopenias

3. **Hematologic abnormalities**
- Normocytic anemia causing fatigue and exercise intolerance
- Thrombocytopenia with bleeding manifestations
- Leukopenia predisposing to recurrent infections

4. **Extrahepatic manifestations**
- Restrictive lung disease from pulmonary infiltration
- Neurodegenerative changes in neuronopathic forms
- Increased risk of Parkinsonian disorders [26]

The pathophysiology involves:
- Macrophage activation syndrome
- Chronic inflammatory state
- Disrupted cellular homeostasis

Optimal management requires:
- Regular comprehensive monitoring
- Early therapeutic intervention
- Multidisciplinary care coordination
- Individualized treatment approaches

XI. DETERRENCE AND PATIENT EDUCATION

Effective management of Gaucher disease involves comprehensive preventive measures and patient education initiatives:

Genetic counseling and screening:
- Focused carrier testing should be prioritized for at-risk demographic groups, especially those of Ashkenazi Jewish ancestry.
- Prenatal genetic testing options for at-risk couples
- Family planning guidance based on genetic risk assessment
- Education about autosomal recessive inheritance patterns

Patient empowerment through education:
- Disease pathogenesis and natural history explanations
- Treatment modality education (including ERT and SRT mechanisms)
- Importance of adherence to monitoring protocols
- Recognition of disease progression warning signs
- Available support resources and patient advocacy groups. [27]

Parkinson's disease risk counseling:
- GBA1 mutation carriers have a 3% risk of Parkinson's by age 70 (increasing to 4% by 80)
- Patients with the condition have a 5% lifetime risk by 70 years of age, increasing to 8% by age 80
- In clinical practice, GBA1 alterations constitute the most commonly observed hereditary risk element for PD and related movement disorders.
- Neurological monitoring recommendations for at-risk individuals [28,29]

Key educational components should address:
- Long-term complication monitoring
- Lifestyle modifications
- Psychosocial support needs
- Emerging treatment options
- Clinical trial participation opportunities

Implementation strategies:
- Multidisciplinary counseling teams
- Culturally sensitive educational materials
- Regular reinforcement of key concepts
- Shared decision-making approaches

XII. ENHANCING HEALTHCARE TEAM OUTCOMES

Optimal care for Gaucher disease, a complex inherited metabolic disorder, requires coordinated efforts from an interprofessional healthcare team. This collaborative approach should include:

1. **Team composition and roles:**
- Physicians (geneticists, hematologists, neurologists) for diagnosis and treatment planning
- Nurse specialists for ongoing patient monitoring and education
- Pharmacists for medication management and adverse effect monitoring
- Physical therapists for mobility and skeletal complications
- Psychosocial support professionals for mental health needs

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 3 May-June 2025, pp: 1951-1958 www.ijprajournal.com ISSN: 2456-4494

2. Essential competencies:
- Thorough understanding of disease pathophysiology
- Knowledge of current diagnostic protocols
- Familiarity with available therapies (ERT, SRT)
- Awareness of potential complications

3. Care coordination:
- Regular interdisciplinary case conferences
- Shared electronic health records for seamless communication
- Patient-centered care plans addressing medical and psychosocial needs
- Appropriate specialist referrals when indicated

4. Professional development:
- Continuing medical education on emerging therapies
- Participation in Gaucher disease registries
- Attendance at specialized conferences and workshops

Implementation benefits:
- Improved treatment adherence
- Enhanced early complication detection
- Better quality of life outcomes
- Reduced hospitalizations
- More efficient resource utilization

ABBREVIATIONS USED

1. **GD -** Gaucher Disease
2. **GBA1 -** Glucosylceramidase Beta 1 (gene)
3. **LSDs -** Lysosomal Storage Disorders
4. **ERT -** Enzyme Replacement Therapy
5. **SRT -** Substrate Reduction Therapy
6. **CNS -** Central Nervous System
7. **MRI -** Magnetic Resonance Imaging
8. **DEXA -** Dual-Energy X-ray Absorptiometry
9. **EEG -** Electroencephalogram
10. **CBC -** Complete Blood Count
11. **PAS -** Periodic Acid-Schiff
12. **PCR -** Polymerase Chain Reaction
13. **FDA -** Food and Drug Administration
14. **HSCT -** Hematopoietic Stem Cell Transplantation (mentioned as "stem cell transplantation" in the text)
15. **IV -** Intravenous (implied in ERT administration)

REFERENCES

[1]. Stone WL, Basit H, Mukkamalla SKR, et al. Gaucher Disease. [Updated 2023 Nov 12]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK448080/.

[2]. Stirnemann, J., Belmatoug, N., Camou, F., Serratrice, C., Froissart, R., Caillaud, C., Levade, T., Astudillo, L., Serratrice, J., Brassier, A., Rose, C., De Villemeur, T. B., & Berger, M. (2017). A review of Gaucher Disease pathophysiology, clinical presentation and treatments. International Journal of Molecular Sciences, 18(2), 441. https://doi.org/10.3390/ijms18020441.

[3]. Ferreira, C. R., & Gahl, W. A. (2016). Lysosomal storage diseases. Translational Science of Rare Diseases, 2(1–2), 1–71. https://doi.org/10.3233/trd-160005.

[4]. Wang, M., Li, F., Zhang, J., Lu, C., & Kong, W. (2022). Global Epidemiology of Gaucher Disease: an Updated Systematic Review and Meta-analysis. Journal of Pediatric Hematology/Oncology, 45(4), 181–188. https://doi.org/10.1097/mph.0000000000002506.

[5]. Kałużna, M., Trzeciak, I., Ziemnicka, K., Machaczka, M., &Ruchała, M. (2019). Endocrine and metabolic disorders in patients with Gaucher disease type 1: a review. Orphanet Journal of Rare Diseases, 14(1). https://doi.org/10.1186/s13023-019-1211-5.

[6]. Linari, S., &Castaman, G. (2022). Hemostatic abnormalities in Gaucher Disease: mechanisms and clinical implications. Journal of Clinical Medicine, 11(23), 6920. https://doi.org/10.3390/jcm11236920.

[7]. Giraldo, P., Andrade- Campos, M., & Morales, M. (2022). Recommendations on the follow- up of patients with Gaucher disease in Spain: Results from a Delphi survey. JIMD Reports, 64(1), 90–103. https://doi.org/10.1002/jmd2.12342.

[8]. Mistry, P. K., Lopez, G., Schiffmann, R., Barton, N. W., Weinreb, N. J., &Sidransky, E. (2016). Gaucher disease: Progress and ongoing challenges. Molecular Genetics and Metabolism, 120(1–2), 8–21. https://doi.org/10.1016/j.ymgme.2016.11.006.

[9]. Mistry, P. K., Lukina, E., Turkia, H. B., Shankar, S. P., Baris, H., Ghosn, M., Mehta, A., Packman, S., Pastores, G., Petakov, M., Assouline, S., Balwani, M., Danda, S.,

Hadjiev, E., Ortega, A., Gaemers, S. J. M., Tayag, R., &Peterschmitt, M. J. (2017). Outcomes after 18 months of eliglustat therapy in treatment- naïve adults with Gaucher disease type 1: The phase 3 ENGAGE trial. American Journal of Hematology, 92(11), 1170–1176. https://doi.org/10.1002/ajh.24877.

[10]. Ringdén O, Groth CG, Erikson A, Granqvist S, Månsson JE, Sparrelid E. Ten years' experience of bone marrow transplantation for Gaucher disease. Transplantation. 1995 Mar 27;59(6):864-70. PMID: 7701581.

[11]. Erikson, A., Groth, C. G., Månsson, J., Percy, A., Ringdén, O., &Svennerholm, L. (1990). Clinical and biochemical outcome of marrow transplantation for Gaucher disease of the Norrbottnian type. Acta Paediatrica, 79(6–7), 680–685. https://doi.org/10.1111/j.1651-2227.1990.tb11535.x.

[12]. Rappeport, J. M., & Ginns, E. I. (1984). Bone-Marrow transplantation in severe Gaucher's disease. New England Journal of Medicine, 311(2), 84–88. https://doi.org/10.1056/nejm198407123110203.

[13]. Chavananon, S., Sripornsawan, P., Songthawee, N., &Chotsampancharoen, T. (2021). Successful treatment of Gaucher disease with matched sibling hematopoietic stem cell transplantation: a case report and literature review. Journal of Pediatric Hematology/Oncology, 43(8), e1153–e1155. https://doi.org/10.1097/mph.0000000000002129.

[14]. Steward, C. G. (2005). Haemopoietic stem cell transplantation for genetic disorders. Archives of Disease in Childhood, 90(12), 1259–1263. https://doi.org/10.1136/adc.2005.074278.

[15]. Somaraju, U. R. R., & Tadepalli, K. (2017). Hematopoietic stem cell transplantation for Gaucher disease. Cochrane Library, 2021(4). https://doi.org/10.1002/14651858.cd006974.pub4.

[16]. Zimran, A., Elstein, D., Schiffmann, R., Abrahamov, A., Goldberg, M., Bar-Maor, J., Brady, R., Guzzetta, P., & Barton, N. (1995). Outcome of partial splenectomy for type I Gaucher disease. The Journal of Pediatrics, 126(4), 596–597. https://doi.org/10.1016/s0022-3476(95)70358-6.

[17]. Sam, R., Ryan, E., Daykin, E., &Sidransky, E. (2021). Current and emerging pharmacotherapy for Gaucher disease in pediatric populations. Expert Opinion on Pharmacotherapy, 22(11), 1489–1503. https://doi.org/10.1080/14656566.2021.1902989.

[18]. Enquist, I. B., Nilsson, E., Ooka, A., Månsson, J., Olsson, K., Ehinger, M., Brady, R. O., Richter, J., & Karlsson, S. (2006). Effective cell and gene therapy in a murine model of Gaucher disease. Proceedings of the National Academy of Sciences, 103(37), 13819–13824. https://doi.org/10.1073/pnas.0606016103.

[19]. Di Rocco, M., Vici, C. D., Burlina, A., Venturelli, F., Fiumara, A., Fecarotta, S., Donati, M. A., Spada, M., Concolino, D., & Pession, A. (2023). Screening for lysosomal diseases in a selected pediatric population: the case of Gaucher disease and acid sphingomyelinase deficiency. Orphanet Journal of Rare Diseases, 18(1). https://doi.org/10.1186/s13023-023-02797-0.

[20]. Bossù, G., Pedretti, L., Bertolini, L., & Esposito, S. (2023). Pediatric Gaucher Disease Presenting with Massive Splenomegaly and Hepatic Gaucheroma. Children, 10(5), 869. https://doi.org/10.3390/children10050869.

[21]. Oliva, P., Schwarz, M., Mechtler, T. P., Sansen, S., Keutzer, J., Prusa, A., Streubel, B., & Kasper, D. C. (2023). Importance to include differential diagnostics for acid sphingomyelinase deficiency (ASMD) in patients suspected to have to Gaucher disease. Molecular Genetics and Metabolism, 139(1), 107563. https://doi.org/10.1016/j.ymgme.2023.107563.

[22]. Garça, M., Correia, S., Goulart, A., & Ávila, P. (2022). Gaucher disease: one of the few causes of massive splenomegaly. European Journal of Case Reports in Internal Medicine. https://doi.org/10.12890/2022_003705.

[23]. Louw, V. J., Fraser, I., & Giraldo, P. (2023). Management goals of type 1 Gaucher disease in South Africa: An expert Delphi consensus document on good clinical practice. PLoS ONE, 18(8), e0290401. https://doi.org/10.1371/journal.pone.0290401.

[24]. Chida, R., Shimura, M., Ishida, Y., Suganami, Y., & Yamanaka, G. (2022). Perinatal lethal Gaucher disease: A case report and review of literature. Brain and Development, 45(2), 134–139. https://doi.org/10.1016/j.braindev.2022.09.006

[25]. Feng, J., Gao, Z., Shi, Z., Wang, Y., & Li, S. (2023). Patient-reported outcomes in Gaucher's disease: a systematic review. Orphanet Journal of Rare Diseases, 18(1). https://doi.org/10.1186/s13023-023-02844-w.

[26]. Lu, W., Chien, Y., Tsai, F., Hwu, W., Chou, Y., Chu, S., Li, M., Lee, A., Liao, C., Wang, C., & Lee, N. (2023). Changing clinical manifestations of Gaucher disease in Taiwan. Orphanet Journal of Rare Diseases, 18(1). https://doi.org/10.1186/s13023-023-02895-z

[27]. Collin-Histed, T., Rosenberg, A., Hopman, N., & Pacey, J. (2023). Understanding patient and parent/caregiver perceptions on gene therapy in Gaucher disease: an international survey. Orphanet Journal of Rare Diseases, 18(1). https://doi.org/10.1186/s13023-022-02576-3.

[28]. Wilke, M. V. M. B., Poswar, F., Borelli, W. V., Tirelli, K. M., Randon, D. N., Lopes, F. F., Pasetto, F. B., Sebastião, F. M., Iop, G. D., Faqueti, L., Da Silva, L. A., Kubaski, F., Schuh, A. F. S., Giugliani, R., & Schwartz, I. V. D. (2023). Follow-up of pre-motor symptoms of Parkinson's disease in adult patients with Gaucher disease type 1 and analysis of their lysosomal enzyme profiles in the CSF. Orphanet Journal of Rare Diseases, 18(1). https://doi.org/10.1186/s13023-023-02875-3.

[29]. Hertz, E., Lopez, G., Lichtenberg, J., Haubenberger, D., Tayebi, N., Hallett, M., &Sidransky, E. (2023). Rapid-Onset dystonia and parkinsonism in a patient with Gaucher disease. Journal of Movement Disorders, 16(3), 321–324. https://doi.org/10.14802/jmd.23074.